Medibio Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.26 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive MEB News and Ratings via Email

Sign-up to receive the latest news and ratings for Medibio and its competitors with MarketBeat's FREE daily newsletter.

About Medibio

Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.77 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Medibio (ASX:MEB) Frequently Asked Questions

What stocks does MarketBeat like better than Medibio?

Wall Street analysts have given Medibio a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medibio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Medibio's key executives?

Medibio's management team includes the following people:
  • Mr. Claude Solitario, Managing Director, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Joint Company Sec. & Director (Age 48, Pay $141.63k)
  • Ms. Renee Stanton-Horne, Operations & Account Mang.
  • Ms. Stephanie Ottens, Investor Relations Director
  • Mr. Josh Purdy, PR Director
  • Dr. Michael Player, Head of Research
  • Dr. Matthew Flax, Head of Algorithm Devel. Team
  • Mr. Archie Defillo M.D., Chief Medical Officer
  • Ms. Jennifer Solitario, Sr. VP of Corp. Health
  • Mr. Massimiliano Grassi, Head of Artificial Intelligence

Who are some of Medibio's key competitors?

What is Medibio's stock symbol?

Medibio trades on the ASX under the ticker symbol "MEB."

How much money does Medibio make?

Medibio has a market capitalization of $0.00 and generates $1.26 million in revenue each year.

What is Medibio's official website?

The official website for Medibio is

How can I contact Medibio?

The company can be reached via phone at 952-222-0551.

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.